Show simple item record

dc.contributor.authorNoone, Declan
dc.contributor.authorPedra, Gabriel
dc.contributor.authorAsghar, Sohaib
dc.contributor.authorO'Hara, Jamie
dc.contributor.authorSawyer, Eileen K.
dc.contributor.authorLi, Nanxin
dc.date.accessioned2019-12-04T05:55:41Z
dc.date.available2019-12-04T05:55:41Z
dc.date.issued2019-11-13
dc.identifierdoi: 10.1182/blood-2019-126576
dc.identifier.citationNoone, D., Pedra, G., Asghar, S., O'Hara, J., Sawyer, E. K., & Li, N. (2019). Prophylactic Treatment in People with Severe Hemophilia B in the US: An analysis of real-world healthcare system costs and clinical outcomes. Blood, 134(supplement 1), 2118. https://doi.org/10.1182/blood-2019-126576
dc.identifier.issn0006-4971
dc.identifier.doi10.1182/blood-2019-126576
dc.identifier.urihttp://hdl.handle.net/10034/622853
dc.description.abstractThe treatment paradigm for people with severe hemophilia B in the US typically involves prophylaxis with factor IX (FIX) replacement therapy, the primary aim of which is to provide sufficient FIX levels to reduce the frequency of bleeding events. The clinical benefits of FIX prophylaxis are well understood, however the cost of FIX products as well as costs associated with healthcare resource utilization present a significant burden to the healthcare system. Substantive costs may also accrue in patients who continue to bleed while on prophylaxis, due to the impact on both short and long-term joint-related outcomes. In the absence of existing data in the US, the 'Cost of Hemophilia Across the USA: a Socioeconomic Survey' (CHESS US) study was conducted to establish a population-based estimate of the real-world US healthcare system burden associated with severe hemophilia. Using data drawn from the CHESS US study, this analysis examines the real-world healthcare system costs and clinical outcomes of people with severe hemophilia B on FIX prophylaxis
dc.publisherAmerican Society of Hematology
dc.relation.urlhttps://ashpublications.org/blood/article/134/Supplement_1/2118/428143/Prophylactic-Treatment-in-People-with-Severe
dc.sourcepissn: 0006-4971
dc.sourceeissn: 1528-0020
dc.subjectImmunology
dc.subjectCell Biology
dc.subjectBiochemistry
dc.subjectHematology
dc.titleProphylactic Treatment in People with Severe Hemophilia B in the US: An Analysis of Real-World Healthcare System Costs and Clinical Outcomes
dc.typeArticle
dc.identifier.eissn1528-0020
dc.contributor.departmentHCD Economics, Daresbury; University of Chester; uniQure
dc.identifier.journalBlood
dc.date.updated2019-12-04T05:55:40Z


This item appears in the following Collection(s)

Show simple item record